Moleculin Biotech (MBRX)

• Market cap: $7.93M
• 1 day: -7.49%
• 5 days: -24.31%
• 1 month: -63.52%
• 3 months: -62.82%
• 6 months: -73.73%
• Year to date: -91.34%
• 1 year: -91.85%
• 5 years: -99.78%
• 10 years: -99.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Employees: 17